论文部分内容阅读
The liguzinediol was a potential drug for the treatment of heart failure with high effect and low safety risk.However,in vivo pharmacokinetic study showed elimination half-life (t1/2) was too short,according to the strategy of drug optimization,prodrugs might be considered as a main method to enhance pharmacokinetic properties.